Neha Patil

ADB CHMINACA

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
CAS Number  1185887-13-1
ChemSpider  48059556
Formula  C21H30N4O2
PubChem CID  68894304
UNII  SL4C60689M
Molar mass  370.24 g/mol
ADB-CHMINACA httpsuploadwikimediaorgwikipediacommonsthu
Legal status  CA: Schedule II DE: Anlage II (Prohibited) US: Schedule I Illegal in Singapore, Sweden, Switzerland

Md php 3fpm adb chminaca 4 meo pvp adb fubinaca


ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.

Contents

Fub amb adb fub adb chminaca jwh018 amb fub china factory direct with fast delivery


Side Effects

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.

Legal status

As of October 29, 2014 Louisiana placed ADB-CHMINACA into Schedule I by emergency scheduling.

Sweden's public health agency suggested to classify ADB-CHMINACA as hazardous substance on November 10, 2014.

ADB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.

The DEA announced its intent to place ADB-CHMINACA into Schedule I of the USA Controlled Substances Act on September 16, 2015.

ADB-CHMINACA is illegal in Switzerland as of December 2015.

References

ADB-CHMINACA Wikipedia


Similar Topics
Erik Gandini
Alex da Kid
Ike Nwankwo
Topics